Showing results (291-300 of 465) with videos related to

Sort By:
Pageof 47
Urologic Oncology|October 6, 2019
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancerVera Genitsch, Attila Kollár, Gillian Vandekerkhove, et al.
Cancers|May 25, 2024
Long-Term Follow-Up of Peritoneal Interposition Flap in Symptomatic Lymphocele Reduction following Robot-Assisted Radical Prostatectomy: Insights from the PIANOFORTE TrialChristopher Goßler, Matthias May, Steffen Weikert, et al.
Oncology Letters|January 2, 2016
Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancerCédric Poyet, Thomas Hermanns, Qing Zhong, et al.
Urologic Oncology|May 8, 2019
BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation studyGeorg C Hutterer, Florian Posch, Lorenz Buser, et al.
World Journal of Urology|January 8, 2024
The landscape of penile cancer research in Germany and Austria: a survey among professors in academic centers holding chair positions and results of a literature searchSemih Sarcan, Ingmar Wolff, Lukas Lusuardi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2013
Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomyEvanguelos Xylinas, Michael Rink, Brian D Robinson, et al.
Clinical Genitourinary Cancer|December 17, 2013
EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancerMatthias May, Maximilian Burger, Sabine Brookman-May, et al.
Translational Oncology|March 26, 2017
High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder CancerDanijel Sikic, Johannes Breyer, Arndt Hartmann, et al.
Molecular Carcinogenesis|January 12, 2018
Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancersSimon C Baker, Volker M Arlt, Radek Indra, et al.
BJU International|February 27, 2024
A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancerMaximilian Haas, Simon U Engelmann, Roman Mayr, et al.
Pageof 47